Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.1.34 (lipoprotein lipase)
7,025 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Molecular mechanisms underlying the ability of heparin to enhance the platelet-aggregating effect of various agonists were studied. Heparin potentiates the aggregating effect of adenosine diphosphate (ADP) and epinephrine, but it is uneffective on the aggregation induced by ristocetin and collagen. Heparin inhibits aggregation induced by thrombin in the presence of plasma, but it is uneffective, or sometimes stimulates aggregation, in the absence of plasma. The effects on the platelet-activating factor- (PAF-acether) induced aggregation are very variable. The late phase of the ADP-induced aggregation is sensitive to proteinase inhibitors, but heparin overcomes this inhibitory effect. Drugs which inhibit remodeling of membrane phospholipids abolish the potentiating effect of heparin, while cyclooxygenase inhibitors do not. The proaggregating effect of heparin subfractions correlates with the lipoprotein lipase activity and, slightly, with the molecular weight, but it does not correlate with the anticoagulant activity. Platelets prelabelled with phosphatidyl[U14C]inositol show a very rapid effect of heparin in triggering phosphatidylinositor breakdown and a cooperative effect with ADP, a known agonist of the 'phosphatidylinositol cycle'. Heparin is also effective in stimulating the labelling of polyphosphoinositides in platelets prelabelled with 32Pi. These results, together with the selective sensitivity to drugs, lead to the conclusion that a stimulatory effect on the very early events of remodeling of membrane phospholipids is involved in the platelet proaggregating effect of heparin.
...
PMID:Molecular events involved in the proaggregating effect of heparin on human platelets. 649 25

Although exposure of platelets to ionophore A23187 causes some activation of phospholipase C, ionophore is an inefficient stimulus for this enzyme. A23187 induces the formation of one-fourth to one-sixth as much diglyceride as does thrombin when comparable amounts of phosphatidylinositol are hydrolyzed. We have shown previously that in the presence of indomethacin thrombin-treated platelets accumulate significant quantitites of diglyceride via inhibition of diglyceride lipase. However, a similar accumulation of diglyceride does not occur when ionophore is used as a stimulus in the presence of indomethacin. Ionophore does not appear to be stimulating the catabolism of diglyceride, since the simultaneous addition of ionophore and thrombin does not impair the formation and metabolism of diglyceride which is promoted by thrombin alone. Further, whereas indomethacin exerts no inhibitory effects upon phospholipase C or the formation of diglyceride in platelets responding to either stimulus, indomethacin does inhibit 1) the loss of arachidonic acid from phosphatidylcholine in response to thrombin and 2) the loss of arachidonic acid from phosphatidylcholine and phosphatidylinositol in response to A23187. We conclude that in A23187-activated platelets, phosphatidylinositol is hydrolyzed primarily by an enzyme other than phospholipase C. This indomethacin-inhibitable enzyme is probably a phospholipase A. Therefore, the full expression of phospholipase C in platelets requires more than a general flux in intracellular calcium.
...
PMID:Differential activation of platelet phospholipases by thrombin and ionophore A23187. 678 55

Human platelets prelabeled with [3H]glycerol exhibited a trasient increase in radioactivity (1.5-fold gain) in 1,2-diacylglycerol when they were exposed to thrombin. An alteration in radioactivity in monoacylglycerol which is derived from diacylglycerol by diacylglycerol lipase, however, was not observed during the whole period of incubation with thrombin. Lysophosphatidylcholine and lysophosphatidylethanolamine gained radioactivity. By contrast, the level of lysophosphatidylinositol plus lysophosphatidylserine did not show any change. When the effects of thrombin on platelet lipids were examined for [3H]arachidonate-labeled platelets, thrombin-activation induced a 15-fold increase in radioactivity in 1,2-diacylglycerol, a subsequent decrease of which was accompanied by accumulation of radioactivity in phosphatidic acid. There was a concurrent release of free arachidonic acid. These findings, taken together with phospholipid alteration analyzed by phosphorus assay upon thrombin-activation, indicate evidence than newly produced diacyglycerol in thrombin-activated platelets may be immediately converted to phophatidic acid by a diacylglycerol kinase rather than metabolized to monoacylglycerol or arachidonic acid by diacylglycerol lipase, and also that arachidonic acid would be mainly released from phosphatidylcholine and phosphatidylethanolamine by a phospholipase A2 activity.
...
PMID:Evidence for predominance of phospholipase A2 in release of arachidonic acid in thrombin-activated platelets: phosphatidylinositol-specific phospholipase C may play a minor role in arachidonate liberation. 681 81

When platelets are stimulated by thrombin, a phosphatidylinositol-specific phospholipase C produces a transient rise in 1,2-diacylglycerol. We have now characterized the hydrolysis of diacylglycerol by platelet membranes using doubly isotopically labeled substrates of defined fatty acid composition. We find that the fatty acid at sn-1 is hydrolyzed faster than that at sn-2 thereby producing a 2-monoacylglycerol intermediate. If hydrolysis had occurred at either position randomly, 1-monoacylglycerol would also be produced. That none was detected indicates that either the sn-1 fatty acid must be cleaved first or that 1-monoacylglycerol is hydrolyzed by monoacylglycerol lipase much faster than 2-monoacylglyceol. The latter possibility was excluded by the finding that 1-monoacylglycerol and 2-monoacylglycerol are hydrolyzed at equal rates by platelet membranes. The diacylglycerol lipase cleaves diacylglycerols with sn-1 palmitate as rapidly as those with sn-1 stearate. Arachidonate at sn-2 is cleaved twice as fast as sn-2 oleate by monoacylglycerol lipase. The two activities probably represent discrete enzymes since monoacylglycerol lipase activity can be separated from diacylglycerol lipase by fractionation on DEAE-Sepharose, although both are contained in the membrane fraction of platelets. That the sequential breakdown of 1,2-diacylglycerol also occurs in intact platelets is indicated by our finding of a transient rise in arachidonoyl-monoacylglycerol in thrombin-stimulated platelets. This provides further evidence for a role of the phospholipase C-diacylglycerol lipase pathway in the release of arachidonic acid.
...
PMID:Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. 682 11

This article reviews the experimental and clinical evidence regarding heparin therapy in the prophylaxis of coronary heart disease. The actions of heparin take place at the vascular endothelium where injected heparin concentrates, and within the bloodstream. At the endothelium heparin acts to prevent endothelial injury, prevent thrombin generation, prevent platelet adhesion to endothelium, and to decrease uptake of serum lipoproteins. Within the bloodstream heparin increases lipoprotein lipase activity and reduces the concentration of atherogenic very low-density lipoproteins. The reduction in lipemia enhances oxygen transfer from blood to the tissues, and decreases thrombin or ADP-induced platelet aggregation. Heparin increases the concentration of high-density lipoproteins. It decreases hypercoagulability and inhibits overactivation of serum complement. Heparin reduced atherosclerosis in most studies in cholesterol-fed animals. In human subjects who had a myocardial infarct at least one year before the onset of treatment, long-term intermittent heparin therapy significantly decreased cardiovascular deaths as compared to control groups.
...
PMID:Heparin and atherosclerosis. A review of old and recent findings. 698 41

Chondroitin sulfate-dermatan sulfate proteoglycans (PG) were isolated from bovine aorta-intima by extraction with 4.0 M guanidinium chloride in the presence of protease inhibitors and purified through cetylpyridinium complexes. The PG were fractionated by CsCl isopyknic centrifugation into three fractions with different chemical composition. The anticoagulant activity of the PG fractions was studied by Stypven time, partial thromboplastin clotting time (PTT), and thrombin time assays. The three PG fractions delayed coagulation in the three assays. The PG fractions did not affect the ADP and collagen-induced platelet aggregation but inhibited the aggregation induced by 0.2 units per ml. of thrombin. The PG fractions released lipoprotein lipase in rabbits when injected, and the enzyme activity released by the major PG fraction was approximately 60 per cent of that of heparin. This PG fraction interacted with serum low density lipoproteins but not with high density lipoproteins. Certain biologic properties are probably due to the presence of dermatan sulfate in the PG fractions. These studies suggest important functional roles for PG in the arterial wall.
...
PMID:Studies of biologic properties of proteoglycans from bovine aorta. 735 13

Human platelets incubated with thrombin and indomethacin (50 microgram/ml) exhibit an accumulation of diglyceride larger and more persistent than that observed for platelets incubated with thrombin alone. The accumulation appears to be due to the impaired metabolism of diglyceride by diglyceride lipase. In preparations of broken platelets, indomethacin leads to inhibition of diglyceride lipase. A similar inhibition can be achieved by the addition of soybean lipoxidase, and both inhibitions can be counteracted by reduced glutathione. Further, hydroperoxyeicosatetraenoic acid (100 microM) markedly depresses diglyceride lipase activity, whereas neither the hydroxy derivative nor eicosatetraenoic acid displays a comparable effect. Indomethacin at concentrations comparable to those impairing diglyceride lipase does not inhibit diglyceride kinase. This report constitutes the first evidence for the functioning of diglyceride lipase in normal stimulated platelets, and points to a possible role for fatty acid hydroperoxides in governing the activity of this enzyme.
...
PMID:Indomethacin-induced accumulation of diglyceride in activated human platelets. The role of diglyceride lipase. 735 67

Endogenous phospholipid metabolism in stimulated human platelets was studied by phosphorus assay of major and minor components following separation by two-dimensional thin-layer chromatography. This procedure obviated the use of radioactive labels. Extensive changes were found in quantities of phosphatidylinositol (PI) and phosphatidic acid (PA) as a consequence of thrombin or collagen stimulation. Thrombin addition was followed by rapid alterations in the amount of endogenous PI and PA. The decrease in PI was not precisely reciprocated by an increase in PA when thrombin was the stimulus. This apparent discrepancy could be explained by removal of a transient intermediate in PI metabolism, such as diglyceride, formed by PI-specific phospholipase C (Rittenhouse-Simmons, S., J. Clin. Invest.63: 580-587, 1979). Diglyceride would be unavailable for PA formation by diglyceride kinase, if hydrolyzed by diglyceride lipase (Bell, R. L., D. A. Kennerly, N. Stanford, and P. W. Majerus. Proc. Natl. Acad. Sci. U. S. A.76: 3238-3241, 1979) to yield arachidonate for prostaglandin endoperoxide formation. Thrombin-treated platelets also accumulated lysophospho-glycerides. Specifically, lysophosphatidyl ethanolamines accumulated within 15s following thrombin addition. Fatty acid and aldehyde analysis indicated phospholipase A(2) activity, with an apparent preference for diacyl ethanolamine phosphoglycerides. In the case of collagen, these changes occurred concomitantly with aggregation and consumption of oxygen for prostaglandin endoperoxide formation.THESE STUDIES OF ENDOGENOUS PHOSPHOLIPID METABOLISM PROVIDE INFORMATION SUPPORTING THE EXISTENCE OF TWO PREVIOUSLY POSTULATED PATHWAYS FOR LIBERATION OF ARACHIDONIC ACID FROM PLATELET PHOSPHOLIPIDS: (a) the combined action of PI-specific phospholipase C plus diglyceride lipase yielding arachidonate derived from PI; and (b) a phospholipase A(2) acting primarily on diacyl ethanolamine phosphoglyceride.
...
PMID:Phospholipid metabolism in stimulated human platelets. Changes in phosphatidylinositol, phosphatidic acid, and lysophospholipids. 740 Mar 15

We recently proposed a new pathway by which arachidonate is released from platelet phosphatidyl inositol after stimulation by either thrombin or calcium ionophore A23187. The initial step in arachidonate liberation involves hydrolysis of phosphatidyl inositol to form 1,2-diacyglycerol which is subsequently hydrolyzed by a diacyglycerol lipase to liberate arachidonate for the prostaglandin and lipoxygenase pathways. Whether this pathway is unique to platelets or accounts for arachidonate release from other tissues has not been previously studied. Thus we have now investigated arachidonate metabolism in mouse fibrosarcoma cells (HSDM1C1) grown in culture. These cells contain approximately 7.6% of their total phospholipid as phosphatidyl inositol in the resting state (range 6.5-8.3%). When bradykinin (12 microM) is added to the fibrosarcoma cells, there is a rapid depletion of membrane phosphatidyl inositol reaching 62 +/- 8% S.D. of baseline values by 15 seconds, falling to 36 +/- 6% by 15 minutes. The drop in membrane phosphatidyl inositol is accompanied by release of arachidonate and PGE2 into the culture medium. The time course of phosphatidyl inositol breakdown and PGE2 formation supports the idea that phosphatidyl inositol breakdown provides he arachidonate for prostaglandin synthesis in mouse fibrosarcoma cells. Crude extracts of HSDM1C1 cells contained sufficient phosphatidyl inositol-specific phospholipase C activity and diacylglycerol lipase activity to account for arachidonate release in these cells.
...
PMID:Bradykinin-stimulated release of arachidonate from phosphatidyl inositol in mouse fibrosarcoma cells. 741 91

Treatment of aspirinated platelets with the electroneutral K+/H+ exchanger nigericin induces a decrease in intraplatelet pH as measured with the intracellular fluorescent indicator BCECF. Under these conditions, the proton permeability of the plasma membrane is unaffected. The addition of thrombin induces a rapid partial recovery of pH(i), which is completely abolished by the Na+/H+ exchanger inhibitor NHA. The effect is also evident in the presence of the PKC inhibitors GF 109203X or staurosporine and in the absence of both external (EGTA-chelated) and internal (BAPTA-chelated) Ca2+. This makes the thrombin-induced activation of the exchanger independent of the involvement of the hitherto described activators, namely PKC and the increase in [Ca2+]i, as well of the recently reported activator arachidonic acid [Cavallini, L., Coassin, M., Borean, A., and Alexandre, A. (1996) Biochem. J. 319, 567-574], whose production requires a high [Ca2+]i. The thrombin-dependent recovery of pH(i) is prevented by the phospholipase C inhibitor ET 18 O-CH3 and is mimicked by the addition of the permeable diglyceride dioctanoyl glycerol (DiC8) exogenously supplied. The effect of thrombin and DiC8 is unaffected by inhibition of diacylglycerol lipase and diacylglycerol kinase. These experiments identify diglyceride as a novel activator of the Na+/H+ exchanger in platelets.
...
PMID:Diacylglycerol mediates the thrombin-induced, protein kinase C and Ca2+ independent activation of the Na+/H+ exchanger in platelets. 900 May 21


<< Previous 1 2 3 4 Next >>

---